ESC 365 - Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac

HFA Premium Access

Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac

Session: Heart failure with reduced ejection fraction (HFrEF) 2

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Doctor B. PARK (Daegu, KR)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Bo Eun PARK

Kyungpook National University Hospital, Daegu (Korea (Republic of))

0 follower

7 more presentations in this session

The usefulness of end-expiratory oxygen partial pressure as a prognostic indicator in patients with heart failure with reduced ejection fraction

Speaker: Doctor T. Nakade (Tokyo, JP)

SGLT2 inhibitors in heart failure with reduced ejection fraction without diabetes mellitus: why are patients outside the magic circle?

Speaker: Doctor D. Santoro (Bari, IT)

Integrated transcriptomic and regulatory RNA sequencing and machine-learning driven analyses identify molecular signatures underlying human heart failure

Speaker: Doctor J. Gulia (Bengaluru, IN)

Cardiac amyloidosis patients with reduced ejection fraction have an increase morbimortality

Speaker: Doctor F. Bauer (Rouen, FR)

Ivabradine improves survival in children with severe chronic heart failure

Speaker: Doctor R. Adorisio (Rome, IT)

Access the full session

Heart failure with reduced ejection fraction (HFrEF) 2

Speakers: Doctor B. PARK, Doctor T. Nakade, Doctor D. Santoro, Doctor J. Gulia, Doctor F. Bauer...

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources